Literature DB >> 11945093

Refractory epilepsy: a progressive, intractable but preventable condition?

Patrick Kwan1, Martin J Brodie.   

Abstract

Intractable seizures are just one manifestation of 'refractory epilepsy', which can be recognized as a distinct condition with multifaceted dimensions, including neurobiochemical plastic changes, cognitive decline and psychosocial dysfunction, leading to dependent behaviour and a restricted lifestyle. The biological basis of 'refractoriness' is likely to be multifactorial, and may include the severity of the syndrome and/or underlying neuropathology, abnormal reorganization of neuronal circuitry, alteration in neurotransmitter receptors, ion channelopathies, reactive autoimmunity, and impaired antiepileptic drug (AED) penetration to the seizure focus. Some of these deleterious changes may be a consequence of recurrent seizures. We hypothesize that 'refractory epilepsy' may be prevented by interrupting this self-perpetuating progression. There is increasing evidence that these patients can be identified early in the clinical course and, thus, be targeted early for effective therapeutic intervention. Failure of two first-line AEDs due to lack of efficacy or poor tolerability should prompt consideration of epilepsy surgery in a patient with a resectable brain abnormality. For the majority not suitable for 'curative' surgery, AEDs should be combined with the aim of achieving 'synergism'. This strategy has the potential to improve outcome by preventing the insidious progression to intractable 'refractoriness' and a downward spiraling quality of life. Copyright 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11945093     DOI: 10.1053/seiz.2002.0593

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  21 in total

1.  Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients.

Authors:  Mehri Maleki; Mohammad Sayyah; Fatemeh Kamgarpour; Morteza Karimipoor; Aida Arab; Anahita Rajabi; Kourosh Gharagozli; Ahmad Reza Shamshiri; Esmaeil Shahsavand Ananloo
Journal:  Iran Biomed J       Date:  2010-07

2.  How to explain multidrug resistance in epilepsy?

Authors:  Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2005 May-Jun       Impact factor: 7.500

Review 3.  Medical therapy of epilepsy: when to initiate treatment and when to combine?

Authors:  Martin J Brodie
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

4.  Comparison between Initial and Recent Surgical Outcome of 15-Year Series of Surgically Remediable Epilepsy.

Authors:  Myoung-Hee Lee; Eun-Ik Son
Journal:  J Korean Neurosurg Soc       Date:  2010-09-30

Review 5.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

7.  Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy.

Authors:  Suvi Liimatainen; Mahdi Fallah; Elham Kharazmi; Maria Peltola; Jukka Peltola
Journal:  J Neurol       Date:  2009-02-28       Impact factor: 4.849

Review 8.  Pathophysiological implications of neurovascular P450 in brain disorders.

Authors:  Chaitali Ghosh; Mohammed Hossain; Jesal Solanki; Aaron Dadas; Nicola Marchi; Damir Janigro
Journal:  Drug Discov Today       Date:  2016-06-14       Impact factor: 7.851

9.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

Review 10.  Epilepsy surgery: eligibility criteria and presurgical evaluation.

Authors:  Philippe Ryvlin; Sylvain Rheims
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.